Malignant Melanoma of the Uvea

  • American Joint Committee on Cancer

Summary of Changes

Iris
  • T1 lesions have been divided into T1a, T1b, and T1c.

  • T1a is denned as tumor limited to the iris not more than 3 clock hours in size.

  • T1b is denned as tumor limited to the iris more than 3 clock hours in size.

  • T1c is defined as tumor limited to the iris with melanomalytic glaucoma.

  • The definition of T2 lesions has been modified, and T2 has been divided by the addition T2a.

  • T2 is defined as tumor confluent with or extending into the ciliary body and/or choroid.

  • T2a is defined as tumor confluent with or extending into the ciliary body and/or choroid with melanomalytic glaucoma.

  • The definition of T3 lesions has been modified, and T3 has been divided by the addition T3a.

  • T3 is defined as tumor confluent with or extending into the ciliary body and/or choroid with extra scleral extension.

  • T3a is defined as tumor confluent with or extending into the ciliary body with extrascleral extension and melanomalytic glaucoma.

Ciliary Body and Choroid
  • The definition of Tl lesions has been modified, and Tl has been divided into Tla, T1b, and T1c.

  • T1 is defined as tumor 10 mm or less in greatest diameter and 2.5 mm or less in greatest height (thickness).

  • T1a is defined as tumor 10 mm or less in greatest diameter and 2.5 mm or less in greatest height (thickness) without extraocular extension.

  • T1b is defined as tumor 10 mm or less in greatest diameter and 2.5 mm or less in greatest height (thickness) with microscopic extraocular extension.

  • T1c is defined as tumor 10 mm or less in greatest diameter and 2.5 mm or less in greatest height (thickness) with macroscopic extraocular extension.

  • The definition of T2 lesions has been modified, and T2 has been divided into T2a, T2b, and T2c.

Keywords

Ciliary Body Uveal Melanoma Great Height Great Diameter Lymphatic Vessel Invasion 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Bibliography

  1. Factors predictive of growth and treatment of small choroidal melanoma: COMS Report No. 5. the Collaborative Ocular Melanoma Study Group. Arch Ophthalmol 115:1537–1544, 1997Google Scholar
  2. Finger PT. Radiation therapy for choroidal melanoma. Surv Ophthalmol 42:215–232, 1997PubMedCrossRefGoogle Scholar
  3. Finger PT. Radiation therapy for choroidal melanoma. Surv Ophthalmol 42:215–232, 1997PubMedCrossRefGoogle Scholar
  4. Markowitz JA, Hawkins BS, Diener-West M, et al: A review of mortality from choroidal melanoma. I. Quality of published reports, 1966 through 1988. Arch Ophthalmol 110:239–244. 1992PubMedCrossRefGoogle Scholar
  5. McLean IW. Uveal nevi and melanomas. In Spencer WH (Ed.): Ophthalmic pathology: an atlas and textbook. Philadelphia: Saunders, 2121–2217, 1996Google Scholar
  6. McLean IW, Burnier MN, Zimmerman LE, et al: Tumors of the Ureal Tract. In: Rosai J. ed. Atlas of Tumor Pathology: Tumors of the Eye and Ocular adnexa, Third Series, Fascicle 12, Washington, DC: Armed Forces Institute of Pathology, 155–214, 1994Google Scholar
  7. Moshfeghi DM, Moshfeghi AA, Finger PT: Enucleation. Surv Ophthalmol, 44:277–301, 2000PubMedCrossRefGoogle Scholar
  8. Packard RB: Pattern of mortality in choroidal malignant melanoma. Br J Ophthalmol 64:565–575, 1980PubMedCrossRefGoogle Scholar
  9. Seddon JM, Albert DM, Lavin PT, et al: A prognostic factor study of disease-free interval and survival following enucleation for uveal melanoma. Arch Ophthalmol 101:1894 – 1899, 1983PubMedCrossRefGoogle Scholar
  10. Shields CL, Shields JA, Shields MB, et al: Prevalence and mechanisms of secondary intraocular pressure elevation in eyes with intraocular tumors. Ophthalmology 94:839–846, 1987PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2002

Authors and Affiliations

  • American Joint Committee on Cancer
    • 1
  1. 1.Executive OfficeChicagoUSA

Personalised recommendations